Welcome to our dedicated page for Tenaya Therapeutics SEC filings (Ticker: TNYA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Tenaya Therapeutics, Inc. (NASDAQ: TNYA) SEC filings page provides access to the company’s publicly filed documents, including current reports on Form 8-K and other registration materials related to its clinical-stage biotechnology activities. Tenaya describes itself as a clinical-stage company developing gene therapies and a small molecule HDAC6 inhibitor that address the underlying drivers of heart disease, and its filings offer additional detail on these efforts.
Through its SEC reports, Tenaya discloses material events such as underwritten public offerings, clinical program updates and financial results. For example, a Form 8-K dated December 11, 2025, outlines the terms of an underwritten public offering of units consisting of common stock and warrants, including expected gross proceeds and key conditions. Other 8-K filings reference quarterly financial results and communications with the U.S. Food and Drug Administration regarding the MyPEAK-1 trial of TN-201.
Investors can use these filings to better understand capital structure changes, including equity offerings and warrant terms, as well as regulatory and clinical milestones that the company reports to the market. The filings also confirm Tenaya’s exchange listing on the Nasdaq Global Select Market under the symbol TNYA and describe the nature of its business as a clinical-stage biotechnology company focused on therapies for genetic cardiomyopathies and heart failure.
On Stock Titan, Tenaya’s filings are paired with AI-powered summaries that highlight key points from documents such as Form 8-K current reports and registration statements. This can help readers quickly identify the main elements of financing transactions, clinical trial disclosures and other material events, while still allowing full access to the original SEC text for detailed review.
Tenaya Therapeutics (TNYA) reported Q3 2025 results. Net loss was $20.3 million, improving from $25.6 million a year ago, as operating expenses fell to $20.9 million from $26.7 million. Research and development declined to $15.4 million and general and administrative to $5.6 million. Interest income was $0.7 million.
Cash and cash equivalents were $56.3 million, with total assets of $105.0 million and stockholders’ equity of $82.9 million as of September 30, 2025. For the nine months, net loss was $70.4 million versus $87.3 million in 2024. The company completed a March 2025 follow‑on offering with net proceeds of approximately $48.8 million and raised $0.9 million via at‑the‑market sales in January. An SVB loan agreement provides the right to draw $10.0 million through December 31, 2025, with up to an additional $20.0 million at the lender’s discretion.
Programs advanced with interim TN‑201 data presented in November; the FDA placed MyPEAK‑1 on clinical hold to standardize monitoring and immunosuppression protocol activities. Tenaya recognized $1.5 million from an $8.0 million CIRM grant for TN‑401 and recorded $1.2 million related to a 2025 workforce reduction. The company believes existing resources, potential loan availability, and recent warrant exercises will fund operations for at least twelve months following filing. Shares outstanding were 166,505,885 as of November 4, 2025.
Tenaya Therapeutics furnished an 8-K under Item 2.02 to announce its financial results for the quarter ended September 30, 2025.
The company attached the full earnings press release as Exhibit 99.1 and noted that the information in Item 2.02 and Item 9.01 (including Exhibit 99.1) is being furnished, not filed, under the Exchange Act.
Tenaya Therapeutics announced that the FDA placed a clinical hold on MyPEAK-1, its Phase 1b/2a trial of TN-201 for MYBPC3-associated hypertrophic cardiomyopathy. The agency requested a protocol amendment primarily to standardize patient monitoring and management of the immunosuppression regimen across trial sites.
The request followed proactive correspondence about future plans for TN-201 and draws on data reviewed by the independent DSMB in summer 2025, which concluded TN-201 had an acceptable safety profile to allow enrollment at 3E13 vg/kg and 6E13 vg/kg. TN-201 has been generally well tolerated, and there have been no new meaningful safety events since that review.
Tenaya is working with the FDA to resolve the hold and intends to resume dosing once protocol changes are implemented at trial sites. The company does not expect this action to impact data milestones or development timelines for TN-201.
Tomohiro Higa, Senior Vice President, Finance of Tenaya Therapeutics, Inc. (TNYA), reported three share dispositions on 08/18/2025 to cover tax withholding related to vested restricted stock units. The filings show sales of 523, 717, and 1,722 shares at a weighted average sales price of $1.253 (individual sale prices ranged from $1.18 to $1.32).
The report lists the reporting person’s beneficial ownership after each sale as 97,777, 97,060, and 95,338 shares respectively, and discloses that the totals include restricted stock units scheduled to vest: 60,844, 58,907, and 54,220 shares. The form was signed by an attorney-in-fact, Jennifer Drimmer Rokovich, on 08/18/2025. No other transactions or derivative holdings are reported in this filing.
Tingley Whittemore, Chief Medical Officer of Tenaya Therapeutics, Inc. (TNYA), reported three separate sales on 08/18/2025 to cover tax withholding for vested restricted stock units. Each sale was executed at a weighted average price of $1.253, with individual trade prices ranging from $1.18 to $1.32. The filings show dispositions of 1,608; 1,608; and 1,837 shares, leaving the reporting person with 176,248; 174,640; and 172,803 shares respectively after each transaction. The filing discloses remaining unvested RSUs that will result in future issuance: 103,132; 98,757; and 93,757 shares referenced in the explanatory footnotes. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person.
Ali Faraz, who serves as Chief Executive Officer and a director of Tenaya Therapeutics, Inc. (TNYA), reported transactions dated 08/18/2025. The Form 4 discloses three separate sales of common stock executed to cover tax-withholding obligations arising from the vesting of restricted stock units (RSUs). The reported sales were 5,720, 3,893, and 4,920 shares at a weighted average sales price of $1.253, with executed prices ranging from $1.18 to $1.32. The filing lists the reporter's beneficial ownership following each transaction as 311,605, 307,712, and 302,792 shares, respectively, which include unvested RSUs of 243,943, 233,318, and 219,881 shares tied to the referenced awards. The form was signed by an attorney-in-fact.
Tenaya Therapeutics, Inc. (TNYA) filed a Form 144 notice for a proposed sale of 5,053 shares of its common stock through Morgan Stanley Smith Barney Operations Department, with an aggregate market value of $6,331.41. The filing lists total shares outstanding as 162,976,102 and an approximate sale date of 08/18/2025. The securities to be sold were acquired as Restricted Stock Units from the issuer on 08/18/2025, showing an acquired amount of 13,750 units and a payment date of 08/18/2025. The filer reports no sales in the past three months and includes the standard representation about nonpublic material information.
Tenaya Therapeutics, Inc. (TNYA) filed a Form 144 reporting a proposed sale of 14,533 shares of its common stock through Morgan Stanley Smith Barney, with an aggregate market value of $18,209.85. The filing lists the Nasdaq Global Select Market as the intended exchange and an approximate sale date of 08/18/2025.
The securities were acquired on 08/18/2025 as Restricted Stock Units from the issuer (total RSUs shown: 39,687), with payment listed as N/A. The filing states there were 162,976,102 shares outstanding and reports "Nothing to Report" for securities sold by the reporting person in the past three months. The notice includes the required representation that the signer is unaware of undisclosed material adverse information about the issuer.
Woodline Partners LP reports warrants convertible into 9,000,000 shares of Tenaya Therapeutics common stock. The filing states the reported warrants are exercisable into 9,000,000 shares and that, on a fully exercisable basis (but subject to contractual limits), those shares correspond to 4.99% of Tenaya's outstanding common stock based on 162,666,931 shares outstanding as of May 1, 2025. The reported voting and dispositive power numbers reflect the shares issuable upon exercise of the warrants.
The filing explains a contractual 4.99% exercise "Blocker" prevents exercise to the extent doing so would result in beneficial ownership above 4.99%, and the filer disclaims that this statement alone proves beneficial ownership for purposes of the Act.